Abstract
To broaden the clinical applicability of peptide-based immunotherapy in breast cancer, there is a need to identify further tumor-associated peptide epitopes that are specific for HLA alleles, in addition to HLA-A2. The HLA- B44 haplotype is one of the most common HLA-B haplotypes, occurring in 10-20% of the population. We performed the structural characterization of HLA class I-bound self-peptides presented by a human breast cancer cell line with a HLA-A68, A32, B40, B44 haplotype, to identify potential tumor-specific antigens. Of 13 sequenced peptides, 1 peptide had the HLA-A68 peptide binding motif and 12 peptides had the HLA-B40, B44 peptide binding motif. One of the latter peptides, FEVRVCACPG, shared 100% homology to residues 270-279 of wild-type P53 protein. Our study, thus, provides direct evidence for the natural processing and presentation of p53 epitope 270-279 by HLA-B40, B44- bearing human breast tumor cells. Epitopes spanning this region of P53 may have potential use for immunotherapy in patients expressing HLA-A2 and -B44 supertypes.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2089-2093 |
| Number of pages | 5 |
| Journal | Clinical Cancer Research |
| Volume | 5 |
| Issue number | 8 |
| State | Published - Aug 1999 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Wild-type p53 epitope naturally processed and presented by an HLA-B haplotype on human breast carcinoma cells. / Papadopoulos, Kyriakos P.; Hesdorffer, Charles S.; Suciu-Foca, Nicole; Hibshoosh, Hanina; Harris, Paul E.
In: Clinical Cancer Research, Vol. 5, No. 8, 08.1999, p. 2089-2093.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Wild-type p53 epitope naturally processed and presented by an HLA-B haplotype on human breast carcinoma cells
AU - Papadopoulos, Kyriakos P.
AU - Hesdorffer, Charles S.
AU - Suciu-Foca, Nicole
AU - Hibshoosh, Hanina
AU - Harris, Paul E.
PY - 1999/8
Y1 - 1999/8
N2 - To broaden the clinical applicability of peptide-based immunotherapy in breast cancer, there is a need to identify further tumor-associated peptide epitopes that are specific for HLA alleles, in addition to HLA-A2. The HLA- B44 haplotype is one of the most common HLA-B haplotypes, occurring in 10-20% of the population. We performed the structural characterization of HLA class I-bound self-peptides presented by a human breast cancer cell line with a HLA-A68, A32, B40, B44 haplotype, to identify potential tumor-specific antigens. Of 13 sequenced peptides, 1 peptide had the HLA-A68 peptide binding motif and 12 peptides had the HLA-B40, B44 peptide binding motif. One of the latter peptides, FEVRVCACPG, shared 100% homology to residues 270-279 of wild-type P53 protein. Our study, thus, provides direct evidence for the natural processing and presentation of p53 epitope 270-279 by HLA-B40, B44- bearing human breast tumor cells. Epitopes spanning this region of P53 may have potential use for immunotherapy in patients expressing HLA-A2 and -B44 supertypes.
AB - To broaden the clinical applicability of peptide-based immunotherapy in breast cancer, there is a need to identify further tumor-associated peptide epitopes that are specific for HLA alleles, in addition to HLA-A2. The HLA- B44 haplotype is one of the most common HLA-B haplotypes, occurring in 10-20% of the population. We performed the structural characterization of HLA class I-bound self-peptides presented by a human breast cancer cell line with a HLA-A68, A32, B40, B44 haplotype, to identify potential tumor-specific antigens. Of 13 sequenced peptides, 1 peptide had the HLA-A68 peptide binding motif and 12 peptides had the HLA-B40, B44 peptide binding motif. One of the latter peptides, FEVRVCACPG, shared 100% homology to residues 270-279 of wild-type P53 protein. Our study, thus, provides direct evidence for the natural processing and presentation of p53 epitope 270-279 by HLA-B40, B44- bearing human breast tumor cells. Epitopes spanning this region of P53 may have potential use for immunotherapy in patients expressing HLA-A2 and -B44 supertypes.
UR - http://www.scopus.com/inward/record.url?scp=0032771492&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032771492&partnerID=8YFLogxK
M3 - Article
C2 - 10473091
AN - SCOPUS:0032771492
VL - 5
SP - 2089
EP - 2093
JO - Clinical Cancer Research
JF - Clinical Cancer Research
SN - 1078-0432
IS - 8
ER -